ATE209902T1 - Neue liposomkomplexe mit erhöhter systemischer verabreichung - Google Patents

Neue liposomkomplexe mit erhöhter systemischer verabreichung

Info

Publication number
ATE209902T1
ATE209902T1 AT97938096T AT97938096T ATE209902T1 AT E209902 T1 ATE209902 T1 AT E209902T1 AT 97938096 T AT97938096 T AT 97938096T AT 97938096 T AT97938096 T AT 97938096T AT E209902 T1 ATE209902 T1 AT E209902T1
Authority
AT
Austria
Prior art keywords
liposomes
expression
highly efficient
liposome complexes
systemic administration
Prior art date
Application number
AT97938096T
Other languages
English (en)
Inventor
Nancy Smyth-Templeton
George N Pavlakis
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE209902T1 publication Critical patent/ATE209902T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT97938096T 1996-08-19 1997-08-01 Neue liposomkomplexe mit erhöhter systemischer verabreichung ATE209902T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2438696P 1996-08-19 1996-08-19
PCT/US1997/013599 WO1998007408A1 (en) 1996-08-19 1997-08-01 Novel liposome complexes for increased systemic delivery

Publications (1)

Publication Number Publication Date
ATE209902T1 true ATE209902T1 (de) 2001-12-15

Family

ID=21820321

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97938096T ATE209902T1 (de) 1996-08-19 1997-08-01 Neue liposomkomplexe mit erhöhter systemischer verabreichung

Country Status (8)

Country Link
US (1) US6413544B1 (de)
EP (1) EP0955999B1 (de)
JP (1) JP4203835B2 (de)
AT (1) ATE209902T1 (de)
AU (1) AU730771B2 (de)
CA (1) CA2263705C (de)
DE (1) DE69708919T2 (de)
WO (1) WO1998007408A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288266B2 (en) * 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
AUPQ002399A0 (en) * 1999-04-28 1999-05-20 Australian National University, The Model membrane systems
EP1754488A1 (de) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
CA2371922C (en) * 1999-05-24 2012-03-27 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
TR199901199A2 (xx) * 1999-05-31 2001-09-21 Kocagöz Tanil Bakteri transformasyon kiti
AUPQ259399A0 (en) 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US6477426B1 (en) * 2000-06-20 2002-11-05 Celsion Corporation System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumors
US7037520B2 (en) 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20060003316A1 (en) * 2002-07-15 2006-01-05 John Simard Immunogenic compositions derived from poxviruses and methods of using same
US20040048260A1 (en) * 2002-09-10 2004-03-11 Fu-Hsiung Chang Transfection of nucleic acid
EP1585504A4 (de) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Proteinstabilisierte liposomale formulierungen pharmazeutischer wirkstoffe
WO2004104032A2 (en) 2003-05-14 2004-12-02 The University Of Iowa Research Foundation Methods and compositions related to high-titer pseudotyped retroviruses
US8034790B2 (en) 2003-12-01 2011-10-11 Introgen Therapeutics Use of MDA-7 to inhibit pathogenic infectious organisms
EP1761248B1 (de) 2004-03-19 2012-05-23 Rodos BioTarget GmbH Kohlehydrat-derivatisierte liposome gegen zelluläre kohlehydrat-erkennungsdomänen von ctl/ctld-lektinen und intrazelluläre freisetzung von therapeutischen wirkverbindungen
US8338366B2 (en) * 2005-03-14 2012-12-25 The Board of Regents of the University of the Texas System Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
JPWO2006101201A1 (ja) * 2005-03-24 2008-09-04 国立大学法人 北海道大学 目的物質を効率的に核内に送達可能なリポソーム
WO2007041206A2 (en) 2005-09-30 2007-04-12 Auburn University Drug delivery nanocarriers targeted by landscape phage
AU2007221470B2 (en) 2006-02-10 2013-02-14 The University Of Cincinnati Phosphatase inhibitor Protein-1 as a regulator of cardiac function
BRPI0710671B8 (pt) 2006-04-07 2021-05-25 Univ Texas uso de um vetor de bacteriofágo viral adenoassociado (aavp) terapêutico para a fabricação de um medicamento para o tratamento e profilaxia de uma doença hiperproliferativa
US8753878B2 (en) 2006-12-22 2014-06-17 Ewos S.A. Process and formulation for immunizing fish in aquaculture systems
WO2008097623A2 (en) * 2007-02-07 2008-08-14 Gradalis, Inc. Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
US9468607B2 (en) * 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
WO2009049083A1 (en) 2007-10-09 2009-04-16 Washington University In St. Louis Particles for imaging
BRPI0907637A8 (pt) 2008-01-25 2018-01-02 P53 Inc biomarcadores p53
US8563690B2 (en) * 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
WO2011084700A1 (en) 2009-12-17 2011-07-14 The Washington University Antithrombotic nanoparticle
CN103096874A (zh) 2010-04-15 2013-05-08 华盛顿大学 前药组合物、前药纳米粒子及其使用方法
CN103201293B (zh) 2010-09-08 2016-04-27 哈洛齐梅公司 评估和鉴定或发展条件活性治疗蛋白的方法
JP2014510045A (ja) 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
EP2741784B1 (de) 2011-03-02 2017-05-17 Board Of Regents, The University Of Texas System Tusc2 therapien
US10040853B2 (en) 2011-09-09 2018-08-07 Fred Hutchinson Cancer Research Center Methods and compositions involving NKG2D inhibitors and cancer
MX2014010750A (es) 2012-03-08 2015-02-05 Halozyme Inc Anticuerpos receptores del factor de crecimiento anti-epidermico condicionalmente activos y metodos de uso de los mismos.
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
DK3690056T5 (da) 2014-01-31 2024-08-26 Factor Bioscience Inc Fremgangsmåder og produkter til fremstilling og indgivelse af nukleinsyre
AU2016218977C1 (en) 2015-02-13 2023-03-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
EP3349730B1 (de) * 2015-09-18 2020-12-02 Dnarx Systeme zur in-vivo-nukleinsäureexpression
LT3370733T (lt) 2015-11-02 2021-10-25 Board Of Regents, The University Of Texas System Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai
JP2018532810A (ja) 2015-11-07 2018-11-08 マルチビア インコーポレイテッド がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物
WO2017216775A2 (en) 2016-06-16 2017-12-21 The Regents Of The University Of California Identification of factor that promotes human hsc self-renewal
JP7099967B2 (ja) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション 幹細胞由来移植片からの増殖性細胞の排除
WO2018035377A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CA3040458A1 (en) 2016-10-12 2018-04-19 Board Of Regents, The University Of Texas System Methods and compositions for tusc2 immunotherapy
JP2020510624A (ja) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
JP2020511521A (ja) * 2017-03-23 2020-04-16 ディーエヌエーアールエックス in vivoでの核酸発現のためのシステム及び方法
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
CA3092162A1 (en) 2018-04-25 2019-10-31 University Of Massachusetts Artificial exosome composition and related methods
CA3099519A1 (en) * 2018-05-08 2019-11-14 University Of Florida Research Foundation, Incorporated Magnetic liposomes and related treatment and imaging methods
CN108653750B (zh) * 2018-06-01 2022-04-22 成都诺恩基因科技有限公司 包裹质粒dna的阳离子脂质体复合物
CA3117112A1 (en) 2018-10-31 2020-05-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Biomarkers and methods of use for radiation-induced lung injury
TW202120551A (zh) 2019-08-12 2021-06-01 美商普瑞諾生物科技公司 藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
EP4413038A1 (de) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1-bindende affimere
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之pd-l1結合多肽
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5206027A (en) * 1990-09-13 1993-04-27 Fuji Photo Film Co., Ltd. Amphipathic compound and liposome comprising the same
AU4528493A (en) * 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest

Also Published As

Publication number Publication date
JP4203835B2 (ja) 2009-01-07
US20020028219A1 (en) 2002-03-07
US6413544B1 (en) 2002-07-02
AU730771B2 (en) 2001-03-15
AU4050297A (en) 1998-03-06
EP0955999B1 (de) 2001-12-05
DE69708919D1 (de) 2002-01-17
WO1998007408A1 (en) 1998-02-26
EP0955999A1 (de) 1999-11-17
CA2263705A1 (en) 1998-02-26
JP2000516630A (ja) 2000-12-12
CA2263705C (en) 2007-12-04
DE69708919T2 (de) 2002-06-27

Similar Documents

Publication Publication Date Title
DE69708919D1 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
Trubetskoy et al. Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly (L-lysine)-antibody conjugate in mouse lung endothelial cells
Kawakami et al. Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes
DE69906977D1 (de) In liposomen verkapselte nukleinsäurekomplexe
CA2270396A1 (en) Cationic reagents for transfection
EP0759694A4 (de) Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen
DE69837819D1 (de) Kondensierte plasmid-liposome komplex zur transfektion
Loughrey et al. A non-covalent method of attaching antibodies to liposomes
ATE172636T1 (de) Liposomales verabreichungssystem für biologisch aktive stoffe
IL130823A0 (en) Peptide-lipid conjugates liposomes and liposomal drug delivery
ATE273320T1 (de) Fusogene liposomen
FI963103A (fi) Ei-virusvektori
AU1724097A (en) Lipids and their use, for example, in liposomes
ES2165492T3 (es) Profarmacos ciclicos de peptidos y acidos nucleicos de peptidos con estabilidad metabolica mejorada y permeabilidad de la membrana celular.
ATE322255T1 (de) Polyamid-oligomere
CA2219119A1 (en) Nucleic acid ligand complexes
DE69830249D1 (de) Zielgerichtete liposomen zur verabreichung von genen
AU1776801A (en) Modular targeted liposomal delivery system
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
WO1999065461A3 (en) Cationic amphiphile micellar complexes
CO5280052A1 (es) Virosomas cationicos dosper
MX9708111A (es) Lipidos cationicos para terapia genica.
CA2051439A1 (en) Liposomal targeting of ischemic tissue

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties